Advocacy at a Glance 12/18/20 Advocacy at a Glance 12/18/20 What Will Actually Get Funded at FDA in FY 21? Read More Advocacy at a Glance 12/18/20 Advocacy at a Glance 12/18/20 Advocacy at a Glance Read More Analysis and Commentary 12/10/20 Analysis and Commentary 12/10/20 COVID-19 Vaccine Update: A Briefing from the FDA Read More Advocacy at a Glance 12/10/20 Advocacy at a Glance 12/10/20 Advocacy at a Glance Read More Analysis and Commentary 12/5/20 Analysis and Commentary 12/5/20 CDRH Update and Future Priorities Read More Advocacy at a Glance 12/5/20 Advocacy at a Glance 12/5/20 Advocacy at a Glance Read More Analysis and Commentary 11/19/20 Analysis and Commentary 11/19/20 Time to Give Thanks -- Once Again Read More Advocacy at a Glance 11/19/20 Advocacy at a Glance 11/19/20 Advocacy at a Glance Read More Analysis and Commentary 11/12/20 Analysis and Commentary 11/12/20 Where $40 Million Might Go for FY 21 Read More Advocacy at a Glance 11/12/20 Advocacy at a Glance 11/12/20 Advocacy at a Glance Read More Analysis and Commentary 11/8/20 Analysis and Commentary 11/8/20 What Happens in the Next Few Months? Read More Advocacy at a Glance 11/8/20 Advocacy at a Glance 11/8/20 Advocacy at a Glance Read More Analysis and Commentary 10/31/20 Analysis and Commentary 10/31/20 Whether There Is or Whether There Isn't Read More Advocacy at a Glance 10/31/20 Advocacy at a Glance 10/31/20 Advocacy at a Glance Read More Analysis and Commentary 10/24/20 Analysis and Commentary 10/24/20 FY 21, FY 22 Appropriations and CDER Priorities Read More Advocacy at a Glance 10/24/20 Advocacy at a Glance 10/24/20 Advocacy at a Glance Read More Analysis and Commentary 10/16/20 Analysis and Commentary 10/16/20 Future Changes in Congressional Committees and the FDA Read More Advocacy at a Glance 10/16/20 Advocacy at a Glance 10/16/20 Advocacy at a Glance Read More Analysis and Commentary 10/9/20 Analysis and Commentary 10/9/20 Webinar on Budget, Workload, and Other Priorities for CDER Read More Advocacy at a Glance 10/9/20 Advocacy at a Glance 10/9/20 Advocacy at a Glance Read More Newer Posts Older Posts
Advocacy at a Glance 12/18/20 Advocacy at a Glance 12/18/20 What Will Actually Get Funded at FDA in FY 21? Read More
Analysis and Commentary 12/10/20 Analysis and Commentary 12/10/20 COVID-19 Vaccine Update: A Briefing from the FDA Read More
Analysis and Commentary 12/5/20 Analysis and Commentary 12/5/20 CDRH Update and Future Priorities Read More
Analysis and Commentary 11/19/20 Analysis and Commentary 11/19/20 Time to Give Thanks -- Once Again Read More
Analysis and Commentary 11/12/20 Analysis and Commentary 11/12/20 Where $40 Million Might Go for FY 21 Read More
Analysis and Commentary 11/8/20 Analysis and Commentary 11/8/20 What Happens in the Next Few Months? Read More
Analysis and Commentary 10/31/20 Analysis and Commentary 10/31/20 Whether There Is or Whether There Isn't Read More
Analysis and Commentary 10/24/20 Analysis and Commentary 10/24/20 FY 21, FY 22 Appropriations and CDER Priorities Read More
Analysis and Commentary 10/16/20 Analysis and Commentary 10/16/20 Future Changes in Congressional Committees and the FDA Read More
Analysis and Commentary 10/9/20 Analysis and Commentary 10/9/20 Webinar on Budget, Workload, and Other Priorities for CDER Read More
